Abstract: The present invention relates to a pharmaceutical composition, a pharmaceutical combined formulation, and a combined formulation kit, each comprising, as active ingredients, an oral antiviral agent and a therapeutic vaccine including a lipopeptide and a poly(I:C) adjuvant. When the pharmaceutical composition, the pharmaceutical combined agent, and the combined formulation kit are administered/used in hepatitis B patients, a remarkable synergy occurs in terms of therapeutic index for chronic hepatitis B, compared to patients who have undergone standard therapy including the administration of conventional antiviral agents, exhibiting the possibility of completely curing the disease.

Abstract: The present invention relates to a recombinant COVID-19 vaccine composition comprising a lipopeptide and a poly(I:C) adjuvant. The vaccine composition for preventing or treating COVID-19, provided in one aspect of the present invention, can greatly induce both a humoral immune response and a cellular immune response to a recombinant COVID-19 antigen, and thus can be developed as a COVID-19 vaccine so as to be commercially and effectively usable.

Abstract: The present invention relates to a recombinant herpes zoster vaccine comprising liposome and lipopeptide and a method for preparing the same. More particularly, a vaccine composition according to the present invention, prepared using Lipo-Pam, which is a composite adjuvant comprising a liposome and various kinds of lipopeptides, and a varicella-zoster virus gE antigen, a Japanese encephalitis virus gE antigen, or a seasonal inactivated influenza virus antigen, highly induces a cell-mediated immune response as well as a humoral immune response so that the composition of the present invention can be commercially useful.

Abstract: Provided are a silicone release film and a protective film for adhesive films and adhesive tapes including the same. The silicone release film may provide excellent delamination characteristics in various peel-off speed ranges regardless of external environmental changes, such as passage of time or temperature changes.

Abstract: The present invention relates to a recombinant herpes zoster vaccine comprising liposome and lipopeptide and a method for preparing the same. More particularly, a vaccine composition according to the present invention, prepared using Lipo-Pam, which is a composite adjuvant comprising a liposome and various kinds of lipopeptides, and a varicella-zoster virus gE antigen, a Japanese encephalitis virus gE antigen, or a seasonal inactivated influenza virus antigen, highly induces a cell-mediated immune response as well as a humoral immune response so that the composition of the present invention can be commercially useful.

Abstract: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds.

Abstract: The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in addition to the entire surface antigen, and a method for preparing the same. The vaccines provide various epitopes and have excellent immunogenicity to induce a strong humoral immune response as well as a cell-mediated immune response.

Abstract: The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Therefore, the adjuvant of the present invention can be very effectively used as an adjuvant in the formulation of preventive and therapeutic vaccines for viral or parasitic infection and cancer.

Abstract: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds.

Abstract: The present invention relates to an HBV vaccine comprising an entire hepatitis B surface antigen of L protein, M protein and S protein, in which the produced antigens form virus-like particles, and a multi-antigen vaccine further comprising an HBV core antigen in addition to the entire surface antigen, and a method for preparing the same. The vaccines provide various epitopes and have excellent immunogenicity to induce a strong humoral immune response as well as a cell-mediated immune response.

Abstract: The present invention relates to an adjuvant comprising a lipopeptide and poly I:C. When the adjuvant of the present invention is used, the level of antigen specific antibody induction is synergistically increased and Th1 type immune response is also induced. Therefore, the adjuvant of the present invention can be very effectively used as an adjuvant in the formulation of preventive and therapeutic vaccines for viral or parasitic infection and cancer.

Abstract: This invention comprises of construction of a recombinant CHO cell line that produces functional mannose binding lectin (MBL) and of special uses of MBL. Specially, use of MBL for development of a therapeutic agent for patients having systemic infection with viruses, bacteria, or fungus is described. More specifically, MBL as a trigger for complement activation and MBL so formulated to activate complement system for the purpose of treating patients with microbial infection.

Abstract: This invention comprises of construction of a recombinant CHO cell line that produces functional mannose binding lectin (MBL) and of special uses of MBL. Specially, use of MBL for development of a therapeutic agent for patients having systemic infection with viruses, bacteria, or fungus is described. More specifically, MBL as a trigger for complement activation and MBL so formulated to activate complement system for the purpose of treating patients with microbial infection.

Abstract: The present invention relates to an adjuvant and vaccine composition containing pre-S of the hepatitis B virus, and more specifically to a modified recombinant pre-S that can enhance immunogenicity of a general vaccine antigen. The present invention also relates to an improved prophylactic Hepatitis B virus (HBV) vaccine and a therapeutic vaccine for the treatment of chronic HBV carriers.

Abstract: A device for carrying artillery shells, each shell having a cylindrical body and a conical head, is disclosed. The device includes an upper body and a lower body. A gripper assembly is connected to the lower body and has an inner circumferential surface corresponding to the cylindrical body. A driving unit pivots the gripper assembly about an axis. A shell-head stopping unit is connected to the lower body at a position which may be adjusted along the length of the lower body. The shell-head stopping unit receives the conical head of a shell to hold the shell in a set position. Also included is a shell-rear stopping unit connected to the gripper assembly and elastically biased upward with respect to the inner circumferential surface of the gripper assembly. The shell-rear stopping unit holds the rear end of the shell in the gripper assembly.